Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.53 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21486245 | 0.89 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTDDAH1POLBNPC1 | |
| SCHEMBL11353975 | 0.84 | POLB (0.65) | SMN1; SMN2HTTDDAH1POLBNPC1 | |
| SCHEMBL612507 | 0.83 | DDAH1 (0.72) | SMN1; SMN2HTTDDAH1POLBNPC1 | |
| SCHEMBL29749508 | 0.83 | DDAH1 (0.72) | SMN1; SMN2HTTDDAH1POLBNPC1 | |
| SCHEMBL7272275 | 0.82 | POLB (0.67) | SMN1; SMN2HTTDDAH1POLBLMNA | |
| SCHEMBL2851401 | 0.82 | PKM (0.68) | SMN1; SMN2HTTDDAH1POLBNPC1 | |
| Hydrochloric Acid SCHEMBL8323737 | 0.81 | PKM (0.71) | SMN1; SMN2HTTDDAH1POLBNPC1 | |
| SCHEMBL379648 | 0.80 | POLB (0.79) | SMN1; SMN2DDAH1POLBNPC1RAB9A | |
| SCHEMBL20707630 | 0.80 | RAB9A (0.67) | SMN1; SMN2HTTPOLBNPC1RAB9A | |
| SCHEMBL25248849 | 0.80 | CHRM1 (0.74) | SMN1; SMN2HTTPOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738041-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738041-B2 | Ferroportin inhibitors | SLC40A1, HAMP, TFRC | SMN1; SMN2 3085/4885HTT 1074/4885DDAH1 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.